13
Participants
Start Date
November 3, 2020
Primary Completion Date
January 1, 2030
Study Completion Date
January 1, 2030
SB-318
No study drug is administered in this study. Subject who received SB-318 in a previous trial will be evaluated in this trial for long-term safety.
SB-913
No study drug is administered in this study. Subject who received SB-913 in a previous trial will be evaluated in this trial for long-term safety.
SB-FIX
No study drug is administered in this study. Subject who received SB-FIX in a previous trial will be evaluated in this trial for long-term safety.
New York University Grossman School of Medicine, New York
University of North Carolina, Chapel Hill
Cincinnati Children's Hospital Medical Center, Cincinnati
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
UCSF Benioff Children's Hospital Oakland, Oakland
Lead Sponsor
Sangamo Therapeutics
INDUSTRY